Equol, combined with estrogen receptors, can reduce the incidence of diseases such as cardiovascular disease, osteoporosis, and breast cancer; more effectively alleviate the symptoms of perimenopausal syndrome; and improve age‐related decline of the uterus and ovaries. Here, ESR1 is linked to osteoporosis.